Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason M Sheltzer

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Science Translational Medicine|September 13, 2019
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trialsAnn Lin, Christopher J Giuliano, Ann Palladino, et al.
Annals of Surgical Oncology|February 24, 2026
ASO Visual Abstract: Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal MetastasesPrincy Gupta, Elizabeth L Godfrey, Kurt S Schultz, et al.
Annals of Surgical Oncology|March 28, 2026
ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal MetastasesPrincy Gupta, Elizabeth L Godfrey, Kurt S Schultz, et al.
Annals of Surgical Oncology|February 3, 2026
Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal MetastasesPrincy Gupta, Elizabeth L Godfrey, Kurt S Schultz, et al.
Elife|November 29, 2019
Micronuclei-based model system reveals functional consequences of chromothripsis in human cellsMaja Kneissig, Kristina Keuper, Mirjam S de Pagter, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Paired CRISPR screens identify mitochondrial metabolism and UBE2H as aneuploid-specific dependencies in human cancer cell linesKlaske M Schukken, Saron M Akalu, Charles Zou, et al.
Biorxiv : the Preprint Server for Biology|August 15, 2020
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activityMarkus Hoffmann, Heike Hofmann-Winkler, Joan C Smith, et al.
Ebiomedicine|March 7, 2021
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activityMarkus Hoffmann, Heike Hofmann-Winkler, Joan C Smith, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
A clinical-stage oncology compound selectively targets drug-resistant cancersKaitlin Long, Debanjan Bhattacharjee, Samuel H Newman-Stonebraker, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Oncogene-like addiction to aneuploidy in human cancersVishruth Girish, Asad A Lakhani, Christine M Scaduto, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Science Translational Medicine|September 13, 2019
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trialsAnn Lin, Christopher J Giuliano, Ann Palladino, et al.
Annals of Surgical Oncology|February 24, 2026
ASO Visual Abstract: Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal MetastasesPrincy Gupta, Elizabeth L Godfrey, Kurt S Schultz, et al.
Annals of Surgical Oncology|March 28, 2026
ASO Author Reflections: New Insights for Personalized HIPEC Strategies in Colorectal Cancer Peritoneal MetastasesPrincy Gupta, Elizabeth L Godfrey, Kurt S Schultz, et al.
Annals of Surgical Oncology|February 3, 2026
Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal MetastasesPrincy Gupta, Elizabeth L Godfrey, Kurt S Schultz, et al.
Elife|November 29, 2019
Micronuclei-based model system reveals functional consequences of chromothripsis in human cellsMaja Kneissig, Kristina Keuper, Mirjam S de Pagter, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Paired CRISPR screens identify mitochondrial metabolism and UBE2H as aneuploid-specific dependencies in human cancer cell linesKlaske M Schukken, Saron M Akalu, Charles Zou, et al.
Biorxiv : the Preprint Server for Biology|August 15, 2020
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activityMarkus Hoffmann, Heike Hofmann-Winkler, Joan C Smith, et al.
Ebiomedicine|March 7, 2021
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activityMarkus Hoffmann, Heike Hofmann-Winkler, Joan C Smith, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
A clinical-stage oncology compound selectively targets drug-resistant cancersKaitlin Long, Debanjan Bhattacharjee, Samuel H Newman-Stonebraker, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Oncogene-like addiction to aneuploidy in human cancersVishruth Girish, Asad A Lakhani, Christine M Scaduto, et al.
Pageof 6